Bespoke Extracts (BSPK) Capital Expenditures (2012 - 2022)

Bespoke Extracts (BSPK) reported Capital Expenditures of $7202.0 for Q1 2022, up 2567.41% sequentially from $270.0 in Q1 2021.

Bespoke Extracts (BSPK) Capital Expenditures (2012 - 2022) Analysis & Trends

Bespoke Extracts (BSPK) has 6 years of Capital Expenditures data on file, last reported at $7202.0 in Q1 2022.

For the quarter ending Q1 2022, Capital Expenditures changed N/A year-over-year to $7202.0; the trailing twelve-month figure through Dec 2022 stood at $7202.0 (changed N/A YoY), and the FY2022 full-year result was $7202.0, changed N/A from the prior year.
Capital Expenditures climbed to $7202.0 in Q1 2022, from $270.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $7202.0 in Q1 2022 to a low of $270.0 in Q1 2021.
A 3-year average of $3315.7 and a median of $2475.0 in 2020 frame the typical range for Capital Expenditures.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	168.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	110.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	1.95 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	99.60 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	39.90 Mn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	1.40 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	51.00 Mn
10	Bespoke Extracts	1.12 Mn	1.11 Mn	234,175.00	-

Download Data